Business Context and Reporting Period
Company: GRI Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2026
Reporting Period: Event-based report regarding a press release issued on January 8, 2026.
Key Financial Metrics
This filing does not contain specific financial statements, revenue, profit, cash flow, or debt figures. The only financial metric disclosed relates to regulatory compliance:
- Stockholders' Equity: The Company believes its stockholders' equity is in excess of the minimum $2.5 million Nasdaq requirement following a public offering completed in December 2025.
Material Changes
Clinical Trial Update: The Company announced additional data from its Phase 2a clinical trial investigating GRI-0621 in patients diagnosed with idiopathic pulmonary fibrosis. The full details are contained in the attached press release (Exhibit 99.1).
Capital Structure: Completion of a public offering in December 2025, which improved the Company's stockholders' equity position.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the dissemination of clinical trial data and the confirmation of compliance with Nasdaq listing standards regarding minimum stockholders' equity.
Risks and Contingencies: No specific risks or contingencies are detailed within the text of this 8-K, other than the inherent uncertainties associated with clinical trial outcomes referenced in the press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific clinical data results regarding GRI-0621 and idiopathic pulmonary fibrosis.
- Verify the final terms and proceeds of the public offering completed in December 2025.
- Confirm the Company's continued compliance with Nasdaq Capital Market listing requirements.